SFT — Sopharma Trading AD Balance Sheet
0.000.00%
- €115.85m
- €253.80m
- €1.18bn
Annual balance sheet for Sopharma Trading AD, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.98 | 3.49 | 6.7 | 6.99 | 7.85 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 107 | 107 | 123 | 144 | 173 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 212 | 213 | 249 | 305 | 367 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 54.1 | 56.7 | 58.2 | 71.1 | 81.2 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 298 | 293 | 329 | 410 | 480 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 205 | 194 | 222 | 262 | 306 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 255 | 244 | 266 | 328 | 368 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 43.4 | 48.3 | 62.9 | 82.9 | 111 |
| Total Liabilities & Shareholders' Equity | 298 | 293 | 329 | 410 | 480 |
| Total Common Shares Outstanding |